Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Cambridge, 3 May 2018
We are excited to announce that Celgene has joined Open Targets expanding our collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets. Celgene is a global biopharmaceutical company with expertise in the discovery, development and commercialisation of innovative therapies for patients with cancer, immune-inflammatory and other unmet medical needs, which will enhance the offerings of the current Open Targets collaborators GSK, Biogen, Takeda, the Wellcome Sanger Institute and the European Bioinformatics Institute (EMBL-EBI).
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
We currently focus on oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease. We believe that evidence generated in the most human relevant systems showing which targets are causing disease will have a significant impact on the successful development of new medicines. To build a good therapeutic hypothesis we need to find not only which targets are involved but also how we might alter complex disease mechanisms, and how predictive laboratory and animal results are for humans. Learn more about our science.
For more information about Open Targets please see this introductory video.